AbbVie to acquire Capstan Therapeutics for $2.1 billion
Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo
Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo
The collaboration aims to enhance the accuracy of physics-based methods with AI models for optimising small molecule medicine discovery and development
Over 100 million cartridges of rh-insulin supplied to Malaysian health ministry; 345,000+ patients served
The pet dog population alone is expected to increase from 21.4 million in 2019 to 51.5 million by 2028
Extended lab space for product development, customer demos, and training
The approval in China is supported by a robust local clinical development program confirming the drug’s safety, tolerability, and efficacy profile
The approval is based on a comprehensive package of analytical, nonclinical, and clinical data
The NovaSeq X system features Illumina's cutting-edge XLEAP-SBS chemistry, offering unmatched throughput, accuracy, and sustainability
Viatel bioresorbable polymers are increasingly used in dental and orthopedic implants
Changhua site meets international regulatory standards for global medical applications
Subscribe To Our Newsletter & Stay Updated